← Leaderboards
Melanie R Haluska
University Of New Mexico Health Scis Ctr
$75,993
Attributed
$75,993
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $34.5K · FY2019–21$50K$37.5K$25K$12.5K$0
'19
'20
'21
Funding mix
By agency
NIH$75,993 · 1
By mechanism
F31$75,993 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Inhibitor/Antagonist”
- Susan Abushakra · Alzheon, Inc.$27,500,000
- Alan D. Palkowitz · Indiana University Indianapolis$10,342,358
- Michael-Christopher Keogh · Epicypher, Inc.$6,845,336
- Terry Roemer · Prokaryotics, Inc.$6,530,728
- Jurgen Bernd Bulitta · State University Of New York At Buffalo$6,175,581
- Aaron Esser-Kahn · University Of Chicago$5,799,408
Research focus
Inhibitor/AntagonistMalignant Neoplasm Of OvaryGuanosine Triphosphate PhosphohydrolasesHomingIn VitroKnock-DownGreater Sac Of PeritoneumCancer CellDiagnosisHematopoieticAnimal ModelCell-Cell AdhesionBoneEngraftmentBone MarrowBaseCell MotilityCellsChemotherapyActinsCancer PatientComputing MethodologiesBlood CirculationModel Design
Grant awards (3)
The Role of Rac1 in Ovarian Cancer Metastasis and Niche Interaction$7,509
F31 · FY2021 · CA · contact PI
The Role of Rac1 in Ovarian Cancer Metastasis and Niche Interaction$34,494
F31 · FY2020 · CA · contact PI
The Role of Rac1 in Ovarian Cancer Metastasis and Niche Interaction$33,990
F31 · FY2019 · CA · contact PI